Showing results (1-10 of 29) with videos related to
Sort By:
Pageof 3
CNS Oncology|November 4, 2014
Antiangiogenic therapies for glioblastomaIsabel Arrillaga-Romany, Andrew D NordenExpert Opinion on Investigational Drugs|December 11, 2013
Current status of antiangiogenic therapies for glioblastomasIsabel Arrillaga-Romany, David A Reardon, Patrick Y WenAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 10, 2026
Approved Targeted Treatments for Pediatric Brain TumorsEric Bouffet, David Neal Franz, Isabel Arrillaga-Romany, et al.The European Journal of Neuroscience|May 1, 2008
Long-lasting alteration in mesocorticolimbic structures after repeated social defeat stress in rats: time course of mu-opioid receptor mRNA and FosB/DeltaFosB immunoreactivityElla M Nikulina, Isabel Arrillaga-Romany, Klaus A Miczek, et al.Oncotarget|November 8, 2017
A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastomaIsabel Arrillaga-Romany, Andrew S Chi, Joshua E Allen, et al.Neuro-Oncology|September 4, 2020
TERT and DNMT1 expression predict sensitivity to decitabine in gliomasJong-Whi Park, Felix Sahm, Bianca Steffl, et al.The Oncologist|April 20, 2022
Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer CareKelly E Irwin, Naomi Ko, Elizabeth P Walsh, et al.Neuro-Oncology|January 23, 2019
Accelerated progression of IDH mutant glioma after first recurrenceJulie J Miller, Franziska Loebel, Tareq A Juratli, et al.Neuro-Oncology|February 22, 2024
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohortYazmin Odia, Matthew D Hall, Timothy Francis Cloughesy, et al.Neuro-Oncology|November 9, 2019
Biological activity of weekly ONC201 in adult recurrent glioblastoma patientsIsabel Arrillaga-Romany, Yazmin Odia, Varun V Prabhu, et al.Pageof 3